Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Imianowski CJ., Kuo P., Whiteside SK., von Linde T., Wesolowski AJ., Conti AG., Evans AC., Baird T., Morris BI., Fletcher NE., Yang J., Poon E., Lakins MA., Yamamoto M., Brewis N., Morrow M., Roychoudhuri R.
<p>OX40 and CD137 are highly coexpressed on tumor-associated Tregs. <b>A,</b> Representative plots showing expression of OX40 and CD137 on resting and activated CD4<sup>+</sup> Tregs, CD4<sup>+</sup> Tconv cells, and CD8<sup>+</sup> T cells from the spleens and tumors of mice inoculated with MC38 cells. <b>B</b> and <b>C,</b> Quantification of resting CD44<sup>−</sup> CD62L<sup>+</sup> (left) and activated CD44<sup>+</sup> CD62L<sup>−</sup> (right) cells within the indicated T-cell populations in the spleen (<b>B</b>) and tumor (<b>C</b>). Data in <b>B</b> and <b>C</b> were analyzed by one-way ANOVA with Tukey correction for multiple comparisons. Bars and error are mean and SEM. ****, <i>P</i> ≤ 0.0001.</p>